Thanks tada. Excellent explanation.

You are jogging my memory because this harkens back to the ASSURE trial and I posted on Stockhouse that I had the impression that apabetalone's reverse cholesterol transport goes along the arteries grabbing the loose fatty plaques, the plaques that are most likely to break loose and cause strokes and heart attacks, and transports them to the liver which happily receives them and then prepares them to be excreted i.e. unlike the CEPT in which the door of the liver is closed. What seems so exciting is that Dr Wong took a different path and it seems to be paying off...we'll see soon. But even if BoM fails I believe there will still be huge value in apabetalone and RVX. Of course the stock will take a big hit but if you are prepared that will be an opportunity just like ti was in 2013.

The learning about the MOA of apabetalone after ASSURE was very rapid and we now know it has a multimodal impact including reverse cholesterol transport.

One think that has been surprising to me is that that stock was at about the same $ level as the pre ASSURE period in 2013 inspite of the tremendous amount of scientific knowledge gained since that trial.

I hope my thinking is not too far off base as I am not a science person.

GLTA

Toinv